ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
9.06
-0.06 (-0.66%)
At close: Mar 6, 2026, 4:00 PM EST
9.13
+0.07 (0.77%)
After-hours: Mar 6, 2026, 7:28 PM EST
ARS Pharmaceuticals Employees
As of December 31, 2024, ARS Pharmaceuticals had 160 total employees, including 162 full-time and 5 part-time employees. The number of employees increased by 134 or 515.38% compared to the previous year.
Employees
160
Change (1Y)
134
Growth (1Y)
515.38%
Revenue / Employee
$854,922
Profits / Employee
-$479,281
Market Cap
895.57M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 160 | 134 | 515.38% |
| Dec 31, 2023 | 26 | 6 | 30.00% |
| Dec 31, 2022 | 20 | 11 | 122.22% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| Valneva SE | 700 |
| Maravai LifeSciences Holdings | 550 |
| Phathom Pharmaceuticals | 371 |
| Arvinas | 246 |
| uniQure | 209 |
| Cullinan Therapeutics | 111 |
| Janux Therapeutics | 109 |
SPRY News
- 12 days ago - ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences - GlobeNewsWire
- 21 days ago - ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock - Seeking Alpha
- 25 days ago - ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting - GlobeNewsWire
- 4 weeks ago - EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to - GlobeNewsWire
- 6 weeks ago - California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use - GlobeNewsWire
- 2 months ago - Bad News For Competitor Turns Into Big Win For ARS Pharma Stock - Benzinga
- 2 months ago - neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) - GlobeNewsWire
- 3 months ago - ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire